Veterinary oncology clinical trials: Design and implementation

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 226-232

  Thamm, Douglas H ^a   Vail, David M ^b  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Canine; Clinical trial; Oncology; Therapeutic agents; Tumor

Indexed keywords

ADVERSE DRUG REACTION; BEAGLE; CLINICAL RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEPHOSPHORYLATION; DOCUMENTATION; DOG; DRUG ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; INFORMED CONSENT; METHODOLOGY; MORBIDITY; MORTALITY; NONHUMAN; ONCOLOGY; PLANNING; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZATION; REGULATORY T LYMPHOCYTE; REVIEW; VETERINARY MEDICINE; VETERINARY ONCOLOGY; ANIMAL; CLINICAL TRIAL (TOPIC); NEOPLASMS; VETERINARY;

ANIMALIA;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; NEOPLASMS; RESEARCH DESIGN;

EID: 84937521737     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2014.12.013     Document Type: Review

References (54)

1. Acevedo P.V., Topmeyer D.L., Rubin E.H. Phase I trial design and methodology for anticancer drugs. Anticancer Drug Development Guide. Preclinical Screening, Clinical Trials, and Approval 2004, 351-362. Humana Press, Totowa, NJ, USA. Second Ed. B.A. Teicher, P.A. Andrews (Eds.).
2. Albrecht T.L., Franks M.M., Ruckdeschel J.C. Communication and informed consent. Current Opinion in Oncology 2005, 17:336-339.
3. Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., Elbourne D., Gotzsche P.C., Lang T. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Annals of Internal Medicine 2001, 134:663-694.
4. Barnard R.A., Wittenburg L.A., Amaravadi R.K., Gustafson D.L., Thorburn A., Thamm D.H. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 2014, 10:1415-1425.
5. Betensky R.A. Conditional power calculations for early acceptance of H0 embedded in sequential tests. Statistics in Medicine 1997, 16:465-477.
6. Booth B., Glassman R., Ma P. Oncology's trials. Nature Reviews Drug Discovery 2003, 2:609-610.
7. Boothe D.M., Slater M.R., Playter R.F. Ethical considerations in clinical research. Journal of the American Veterinary Medical Association 1992, 200:1616-1621.
8. Burton J.H., Mitchell L., Thamm D.H., Dow S.W., Biller B.J. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. Journal of Veterinary Internal Medicine 2011, 25:920-926.
9. Carlsten K.S., London C.A., Haney S., Burnett R., Avery A.C., Thamm D.H. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. Journal of Veterinary Internal Medicine 2012, 26:135-141.
10. Carsten R.E., Hellyer P.W., Bachand A.M., LaRue S.M. Correlations between acute radiation scores and pain scores in canine radiation patients with cancer of the forelimb. Veterinary Anaesthesia and Analgesia 2008, 35:355-362.
11. Cox A.C., Fallowfield L.J., Jenkins V.A. Communication and informed consent in phase 1 trials: A review of the literature. Supportive Care in Cancer 2006, 14:303-309.
12. Dagher R.N., Pazdur R. The phase III clinical cancer trial. Anticancer Drug Development Guide. Preclinical Screening, Clinical Trials, and Approval 2004, 401-410. Humana Press, Totowa, NJ, USA. Second Ed. B.A. Teicher, P.A. Andrews (Eds.).
13. Fergusson D., Aaron S.D., Guyatt G., Hebert P. Post-randomisation exclusions: The intention to treat principle and excluding patients from analysis. British Medical Journal 2002, 325:652-654.
14. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
15. Friedman L.M., Furberg C.D., DeMets D.L. Fundamentals of Clinical Trials 1985, 51-69. PSG Publishing, Littleton, MA, USA. Second Ed.
16. Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Disease 1961, 13:346-353.
17. Gray R., Manola J., Saxman S., Wright J., Dutcher J., Atkins M., Carducci M., See W., Sweeney C., Liu G., et al. Phase II clinical trial design: Methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clinical Cancer Research 2006, 12:1966-1969.
18. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
19. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., Li S., Pan Z., Thamm D.H., Miller R.A., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:13075-13080.
20. Ishizuka N., Ohashi Y. The continual reassessment method and its applications: A Bayesian methodology for phase I cancer clinical trials. Statistics in Medicine 2001, 20:2661-2681.
21. Jayson G., Harris J. How participants in cancer trials are chosen: Ethics and conflicting interests. Nature Reviews. Cancer 2006, 6:330-336.
22. Kamb A., Wee S., Lengauer C. Why is cancer drug discovery so difficult?. Nature Reviews Drug Discovery 2007, 6:115-120.
23. Khanna C., Lindblad-Toh K., Vail D., London C., Bergman P., Barber L., Breen M., Kitchell B., McNeil E., Modiano J.F., et al. The dog as a cancer model. Nature Biotechnology 2006, 24:1065-1066.
24. Kummar S., Gutierrez M., Doroshow J.H., Murgo A.J. Drug development in oncology: Classical cytotoxics and molecularly targeted agents. British Journal of Clinical Pharmacology 2006, 62:15-26.
25. Kummar S., Kinders R., Rubinstein L., Parchment R.E., Murgo A.J., Collins J., Pickeral O., Low J., Steinberg S.M., Gutierrez M., et al. Compressing drug development timelines in oncology using phase '0' trials. Nature Reviews. Cancer 2007, 7:131-139.
26. Lachin J.M. A review of methods for futility stopping based on conditional power. Statistics in Medicine 2005, 24:2747-2764.
27. Lee J.J., Feng L. Randomized phase II designs in cancer clinical trials: Current status and future directions. Journal of Clinical Oncology 2005, 23:4450-4457.
28. Lee J.J., Lieberman R., Sloan J.A., Piantadosi S., Lippman S.M. Design considerations for efficient prostate cancer chemoprevention trials. Urology 2001, 57:205-212.
29. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
30. Mack G.S. Cancer researchers usher in dog days of medicine. Nature Medicine 2005, 11:1018.
31. Michaelis L.C., Ratain M.J. Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clinical Cancer Research 2007, 13:2400-2405.
32. Moher D., Schulz K.F., Altman D.G. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Annals of Internal Medicine 2001, 134:657-662.
33. Montori V.M., Guyatt G.H. Intention-to-treat principle. Canadian Medical Association Journal 2001, 165:1339-1341.
34. Nguyen S.M., Thamm D.H., Vail D.M., London C.A. Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2013, 10.1111/vco.12032.
35. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews. Cancer 2008, 8:147-156.
36. Paoloni M., Webb C., Mazcko C., Cherba D., Hendricks W., Lana S., Ehrhart E.J., Charles B., Fehling H., Kumar L., et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS ONE 2014, 9. e90028.
37. Paoloni M.C., Tandle A., Mazcko C., Hanna E., Kachala S., Leblanc A., Newman S., Vail D., Henry C., Thamm D., et al. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNFα to cancer vasculature. PLoS ONE 2009, 4. e4972.
38. Paoloni M.C., Mazcko C., Fox E., Fan T., Lana S., Kisseberth W., Vail D.M., Nuckolls K., Osborne T., Yalkowsy S., et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: A comparative oncology study in dogs. PLoS ONE 2010, 5. e11013.
39. Potter D.M. Phase I studies of chemotherapeutic agents in cancer patients: A review of the designs. Journal of Biopharmaceutical Statistics 2006, 16:579-604.
40. Pryer N.K., Lee L.B., Zadovaskaya R., Yu X., Sukbuntherng J., Cherrington J.M., London C.A. Proof of target for SU11654: Inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 2003, 9:5729-5734.
41. Rosner G.L., Stadler W., Ratain M.J. Randomized discontinuation design: Application to cytostatic antineoplastic agents. Journal of Clinical Oncology 2002, 20:4478-4484.
42. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989, 10:1-10.
43. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001, 344:783-792.
44. Stadler W.M. The randomized discontinuation trial: A phase II design to assess growth-inhibitory agents. Molecular Cancer Therapeutics 2007, 6:1180-1185.
45. Stadler W.M., Rosner G., Small E., Hollis D., Rini B., Zaentz S.D., Mahoney J., Ratain M.J. Successful implementation of the randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. Journal of Clinical Oncology 2005, 23:3726-3732.
46. Tsong Y., Chen W.J. Noninferiority testing beyond simple two-sample comparison. Journal of Biopharmaceutical Statistics 2007, 17:289-308.
47. Twombly R. Slow start to phase 0 as researchers debate value. Journal of the National Cancer Institute 2006, 98:804-806.
48. Vail D.M., von Euler H., Rusk A.W., Barber L., Clifford C., Elmslie R., Fulton L., Hirschberger J., Klein M., London C., et al. A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2012, 26:598-607.
49. Veterinary Cooperative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Veterinary and Comparative Oncology 2011, Veterinary Cooperative Oncology Group. 10.1111/j.1476-5829.2011.00283.x.
50. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs - Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clinical Cancer Research 1998, 4:1079-1086.
51. Waters D.J., Wildasin K. Cancer clues from pet dogs. Scientific American 2006, 295:94-101.
52. Whitehead J. Stopping clinical trials by design. Nature Reviews Drug Discovery 2004, 3:973-977.
53. Wittenburg L.A., Gustafson D.L., Thamm D.H. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clinical Cancer Research 2010, 16:4832-4842.
54. Zohar S., Chevret S. Phase I (or phase II) dose-ranging clinical trials: Proposal of a two-stage Bayesian design. Journal of Biopharmaceutical Statistics 2003, 13:87-101.